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Key structures of bacterial peptidoglycan and lipopolysaccharide
triggering the innate immune system of higher animals:
Chemical synthesis and functional studies
By Shoichi KUSUMOTO,1,† Koichi FUKASE2 and Tetsuo SHIBA3
(Communicated by Satoshi   OMURA, M.J.A.)
Abstract: Chemistry-based investigation is reviewed which led to identi cation of the
active entities responsible for the immunostimulating potencies of peptidoglycan and lipopoly-
saccharide. Though these glycoconjugates which ubiquitously occur in wide range of bacteria
as the essential components of their cell envelopes have long been known to enhance the immu-
nological responses of higher animals, neither the precise chemical structures required nor the
mechanism of their action had been elucidated until early 1970s. Chemical synthesis of par-
tial structures of peptidoglycan proved N-acetylmuramyl-L-alanyl-D-isoglutamine to be the mini-
mum structure responsible for the activity and led to later identi cation of its receptor protein
Nod2 present in animal cells. Another active partial structure of peptidoglycan, g-D-glutamyl-
meso-diaminopimelic acid, and its receptor Nod1 were also identi ed as well. With regard to
lipopolysaccharide, its glycolipid part named lipid A was puri ed and the structure studied.
Chemically synthesized lipid A according to the newly elucidated structure exhibited full activity
described for lipopolysaccharide known as endotoxin. Synthetic homogeneous lipid A and its struc-
tural analogues and labeled derivatives enabled precise studies of their interaction with receptor
proteins and the mechanism of their action. Chemical synthesis of homogeneous partial structures
of peptidoglycan and lipopolysaccharide gave unequivocal evidences for the concept that de nite
small molecular parts of these complex macromolecular bacterial glycoconjugates are speci cally
recognized by their respective receptors and trigger our defense system now widely recognized as
innate immunity.
Keywords: chemical synthesis, muramyl peptides, lipid A, peptidoglycan, lipopolysaccharide,
innate immunity
Introduction
Bacterial cells and some of their typical com-
ponents have long been known to enhance the
immunological response of higher animals. When
simultaneously applied with antigenic proteins to ex-
perimental animals, heat-killed Mycobacterium cells,
for example, strongly enhances the production of
speci c antibodies against the relevant antigens.1)
Endotoxin of Gram-negative bacteria was also known
as one of the most potent immunostimulants.2) In-
tensive studies have been carried out by microbiolo-
gists, biochemists, and immunologists to understand
the details of these highly interesting phenomena and
their molecular mechanism. Until early 1970s, two
typical bacterial glycoconjugates, i.e., peptidoglycan
(PGN) and lipopolysaccharide (LPS), the latter
being the active entity of endotoxin, were shown to
be major active cell components responsible for the
immunostimulative function attributed to bacterial
cells.2),3) PGN is a vital cell wall component shared
by all types of bacteria, while LPS is an essential
structural element of the outer membrane present in
all Gram-negative bacterial cells. No information was,
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62010 The Japan Academyhowever, available of their active structures because
of the complex and heterogeneous structures of these
bacterial high molecular weight glycoconjugates. In
view of such situation, we anticipated the existence
of a general defense mechanism of higher animals,
where ubiquitous, typical bacterial cell components
essential for their survival are recognized as alarm
signals of infection and trigger the host system against
invading microbes. We thus started our chemical in-
vestigation toward characterization of the key struc-
tures responsible for the important functions of these
bacterial glycoconjugates. By the aid of our chemical
syntheses, we succeeded in unequivocal determina-
tion of the de nite structures essential for the im-
munostimulating actions of both PGN and LPS in
collaboration with many research groups world wide.
Later discovery of the Toll-like receptor (TLR)
family at the end of the twentieth century led to
unveiling the system of innate immunity, which
takes the major part of the  rst line defense of higher
animals against bacteria, viruses and other invading
microbes before the more e ective and well-known
acquired immunity system based on the speci c
antigen/antibody recognition comes into action.4)
Our chemistry-based approach in collaboration with
bioscientists further led us to elucidation of the de-
tailed mechanism of recognition of these bacterial
components as representative initial players in the
innate immune systems.
Muramyl peptides as the immunostimulative
principle of bacterial peptidoglycan
The early observation by Freund that Mycobac-
terium cells induces the systemic activation of im-
munological responses of higher animals1) prompted
further investigations which led to the conclusion
that such activation is not restricted to Mycobacteria
alone but other common bacterial cells also exhibit
the same ability as well. This ability was referred to
as immunoadjuvant activity or more simply adju-
vant activity. More importantly, PGN shared by all
bacterial cells was then proposed to be responsible
for the activity. PGN is ubiquitously distributed
both in Gram-positive and -negative bacterial cells
as the major and vital component of their cell enve-
lope and protects the life process in the cells from
mechanical, osmotic and other stresses from outside.
Chemically, PGN has a three dimensional stable net-
work structure composed of b(1-4) glycan main
chains and peptide bridges.5),6) The latter interlinks
the former glycan chains of alternating N-acetyl-D-
glucosamine (2-acetamdio-2-deoxy-D-glucose, GlcNAc)
and N-acetylmuramic acid (MurNAc). Further in-
vestigation by French and Japanese research groups
showed that disaccharide (GlcNAc-MurNAc)-oligo-
peptide fractions obtained by limited enzymatic
digestion of PGN exhibited de nite e ects of immu-
nostimulation. However, neither isolation nor char-
acterization of the smallest de nite structure respon-
sible for the function was possible because of the
limited amount of the starting natural PGN and
extreme dif culty in the isolation of homogeneous
partial hydrolysis products.
In early 1970s we joined this research  eld and
started chemical synthesis of several N-acetylmuramyl
(MurNAc) peptides corresponding to the proposed
partial structure of the lysine-type PGN (Fig. 1).7),8)
Among the compounds synthesized (Fig. 2), MurNAc-
L-alanyl-D-isoglutamine (muramyl dipeptide, MDP,
1) and MurNAc-tri- and -tetrapeptides (2 and 3)
enhanced immune responses of guinea pigs against a
given protein antigen in manners similar to those
of natural peptidoglycan preparations as tested in
standard in vivo test systems used that time.7) By
contrast, neither MurNAc-L-alanine nor the tetra-
peptide devoid of the MurNAc moiety showed such
activity. French research group also concluded MDP
(1) as the minimum adjuvant active structure even
slightly earlier than us but we were completely inde-
pendent.9),10)
These were a direct evidence that the adjuvant
activity of natural macromolecular PGN to enhance
the general immunological responses of higher ani-
mals can be reproduced by a synthetic de nite mole-
cule of MDP whose molecular weight is only as low
as 538. This clear conclusion was  rst drawn by the
use of homogeneous synthetic preparations free from
any contaminants of bacterial origin.
In view of the strict structural requirement for
the adjuvant activity observed with various struc-
tural analogues of MDP,3),11),12) the presence of its
speci c receptor in/on host animal cells was ex-
pected. In spite of various e orts, however, we have
to wait almost thirty years, until the receptor for
MDP was identi ed as described below. For example,
we synthesized 14C-labeled MDP as a probe to detect
its binding proteins,13) but investigations with this
labeled compound did not give any satisfactory result.
With regards to the peptide chain, the dipeptide
linked to the MurNAc residue is suf cient for the full
323 Key bacterial surface molecules triggering innate immune system No. 4]activity, no distinct di erence being observed among
the potency of MurNAc-di-, -tri-, and -tetrapeptides.7)
Our early synthesis of a disaccharide, GlcNAc-
MurNAc, indicated that its dipeptides conjugate
has more potent immunostimulating activity than
MDP.14),15) In order to systematically examine the
e ect of the glycan chain length on the activity,
we synthesized repeating b(1-4) oligosaccharides of
alternating GlcNAc and MurNAc residues corre-
sponding to the common backbone structure of
bacterial PGN.16)
Synthesis was achieved by iteration of a reaction
series of glycosyl activation, coupling and deprotec-
tion for the formation of a sequence of di-, tetra-,
and octasaccharides as illustrated in Fig. 3. Thus,
N-2,2,2-trichloroethoxycarbonylated (Troc) 2,2,2-
trichloroacetimidates were used as glycosyl donors
which was expected to assure ef cient and selective
formation of b-glycosidic linkage of 2-amino-2-deoxy
sugars. Coupling of 4,6-O-benzylidene-N-Troc imidate
(4) with an N-Troc-muramic acid acceptor (5), in
fact, a orded desired protected b(1-4) disaccharide
(6) in an excellent yield. A part of the disaccharide
(6) was converted to a disaccharide donor (7),
whereas the other part of the same 6 gave a disac-
charide acceptor (8) by regioselective reductive
opening of the benzylidene ring. Coupling of the two
components gave a repeating tetrasaccharide (9),
which was again converted to both tetrasaccharide
donor and acceptor for the preparation of octasac-
Fig. 1. Schematic representation of peptidoglycan of Staphylococcus aureus.
Fig. 2. Structures of N-acetylmuramyl dipeptide (1), tripeptide (2), and tetrapeptide (3) chemically synthesized.
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groups followed by N-acetylation, ester hydrolysis,
and coupling with a dipeptide component at every
MurNAc residue, and  nal hydrogenolytic deprotec-
tion a orded the largest partial structure of PGN 11
ever obtained synthetically. The corresponding tetra-
saccharide and disaccharide with the dipeptide linked
to each MurNAc residue were also prepared from 9,
and 6, respectively.16),17)
All the above synthetic PGN fragments showed
de nite immunostimulating activities similar to that
of MDP. When their tumor necrosis factor-a (TNF-
a)-inducing potencies were quantitatively compared
by the aid of enzyme-linked immunosorbent assay
(ELISA), MDP proved to be most active and the po-
tency decreased as the glycan chain becomes longer
from di-, tetra- to octasaccharides. This was contrary
to our expectation drawn from the early experiments
with soluble PGN.18) Our result obtained with the
synthetic de nite molecules corresponding to larger
PGN fragments was con rmed soon by using the re-
ceptor protein Nod2 described below: MDP activates
the signaling system more ef ciently than its oligo-
saccharide derivatives.17) Our present understanding
should therefore be that the soluble PGN might
activate animal cells not directly through Nod2 (see
Fig. 3. Synthetic scheme for a repeating octasaccharide linked to four dipeptides (11).
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tained yet unknown other active components of bac-
terial origin.
Inohara et al. and another group identi ed in
the meantime two cytoplasmic proteins named Nod1
and Nod2 which belong to the family of Nod-LRR
proteins. Of the two, Nod2 was concluded to be a
speci c receptor for MDP, which has been looked for
30 years after the discovery of MDP as the minimal
adjuvant active structure of PGN.19) Nod1 was also
concluded by the use of our synthetic specimen to
be a receptor for a dipeptide, g-D-glutamyl-meso-
diaminopimelic acid, which is another minimal active
structure of meso-diaminopimelic acid (meso-DAP)-
type PGN.20),21) This type of PGN, which occurs in
the cell envelope of most of Gram-negative bacteria
and Gram-positive bacilli, contains meso-DAP in
place of L-lysine in the above described Lys-type
PGN (Fig. 1).6),22) On recognition of their respective
ligands, these receptors trigger the intracellular sig-
naling cascade to start the innate immune defense
system against invading bacteria. Our synthetic
specimens contributed to the unequivocal identi -
cation of the ligands of both Nod1 and Nod2. The
mechanism of the cell activation after the ligand
recognition is being investigated in more details.23)
More recently various peptidoglycan fragments
were found to be secreted from growing bacterial
cells into the medium.24) Contact with such environ-
mental bacterial fragments in daily life is expected to
play certain roles in developing the innate immune
system of infants.
Lipid A as the endotoxic active principle
of lipopolysaccharide
Characterization of the active principle of lipo-
polysaccharide (LPS), a typical cell surface compo-
nent of Gram-negative bacteria, became the next
main target of our research after identi cation of
MDP. LPS was  rst described under the name of
endotoxin in 1892 by Pfei er as a highly toxic com-
ponent  rmly bound to cells of Vibrio cholerae which
is a causal bacterium of cholera.25) Later all Gram-
negative bacterial cells were found to contain endo-
toxin irrespective of their pathogenicity. Westphal
and L€ uderitz elaborated an ef cient aqueous phenol
extraction procedure of LPS from cells and showed
protein-free LPS exhibits all endotoxic activities.26)
LPS induces high fever, septic shock and in serious
cases even death of experimental animals. Similar
e ects were observed with human, so that LPS
has been causing serious clinical problems even at
present. LPS has attracted interests of researchers
because it exhibits, in addition to these detrimental
activities, bene cial functions to activate immuno-
logical system of higher animals, for example, potent
antitumor activity being known for it.
LPS is a common and characteristic component
of the cell surface architecture of Gram-negative bac-
teria, constituting the outer lea et of the lipid bilayer
called outer membrane located outside the PGN layer
of the cells. Chemically, LPS consists of covalently
bound three distinct parts, namely, O-antigenic poly-
saccharide, core oligosaccharide, and glycolipid. West-
phal and L€ uderitz then reported selective cleavage of
the linkage between the latter two parts by mild acid
hydrolysis and found the glycolipid, which they
named ‘‘lipid A’’, retains full endotoxic activity.27)
The chemical structure of lipid A was intensively
studied by their group.
Lipid A is an amphiphilc molecule consisting of
covalently bound hydrophilic part of phosphorylated
carbohydrate and lipophilic long chain fatty acyl
groups. Preparations of lipid A from bacterial cells
are always mixtures of molecular species with di er-
ent number and/or locations of acyl groups. Its
strong tendency to aggregate made puri cation of
lipid A quite dif cult in earlier times so that homo-
geneous molecular species of lipid A had never been
available. The structure of lipid A from Salmonella
minnesota was deduced as 12 (Fig. 4) for such a mix-
ture. According to the proposal, a glucosamine b(1-6)
disaccharide phosphorylated at the 1- and 4’-positions
represents the hydrophilic backbone, which is acy-
lated at the two amino and 3-, 4-, and 6’-hydroxy
groups.28),29) The 3’-hydroxy group was thought to
be the linkage position of the core oligosaccharide
and therefore expected to remain not modi ed in
Fig. 4. Old proposed structure of Salmonella lipid A.
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saccharide part. Most of the fatty acid components
were of 3-hydroxylated saturated types with straight
carbon chains. Among them, (R)-3-hydroxylated tetra-
decanoic acid was the major one. A certain propor-
tion of nonhydroxylated acids were always present.
We started chemical synthesis of the proposed
structure of lipid A to prove whether this particular
molecule is responsible for the activity described for
bacterial endotoxin. Since the exact positions of acy-
lation in bacterial lipid A was not  xed until that
time, our synthesis targeted at fully acylated struc-
tures using tetradecanoic (myristic) acid and (R)-3-
hydroxytetradecanoic acid as acyl components. Im-
portant keys for successful synthesis were: 1) pre-
paration of optically pure 3-hydroxy fatty acids, 2)
ef cient formation of chemically labile glycosyl phos-
phates, 3) selective protection and deprotection of
hydroxy groups. Synthetic lipid A analogues of the
 rst generation were obtained by solving all these
problems.30),31) Contrary to our expectation, the
preparations unfortunately did not show any typical
endotoxic activity.32) This quite disappointing result
must mean either the proposed structure of lipid A
was incorrect or the concept was wrong that lipid
A is the endotoxic entity of LPS. The possible most
essential approach to characterize the endotoxic
principle at that moment was determination of the
exact molecular structure of lipid A including the
architecture of the hydrophilic backbone as well
as the distribution and chain lengths of fatty acyl
groups.
To do this, a homogeneous molecular species has
to be isolated: lipid A preparation from Escherichia
coli Re mutant was selected as the substrate because
this species was known to produce rather homo-
geneous lipid A. Selective removal of the chemically
labile glycosyl phosphate of E. coli lipid A followed
by methyl esteri cation gave a mixture, which was
soluble in organic solvents and suitable for chromato-
graphic puri cation. The major component of lipid A
was thus isolated for the  rst time in a chemically
pure form as a dimethyl ester of monophosphory-
lated derivative. Detailed high  eld NMR spec-
troscopic analysis of the puri ed specimen led to
conclude that the previously proposed hydrophilic
backbone structure is correct. The positions of direct
acylation are the two amino and two hydroxy groups
at the 3-, 3’-positions of the b(1-6)glucosamine disac-
charide. According to our composition analysis, the
puri ed lipid A contains six fatty acids, i.e., four
(R)-3-hydroxytetradecanoic acids and each one of
dodecanoic and tetradecanoic acids.33) Based on this
information, the structure of a previously isolated
biosynthetic precursor of lipid A, which contains
only four 3-hydroxytetradecanoic acids, should hence
be rationally proposed as 13. The complete structure
of mature lipid A of E. coli Re mutant was then con-
cluded as 14 through determination of the positions
of the remaining two nonhydroxylated acids by selec-
tive chemical degradation and soft ionization MS
analysis of the puri ed lipid A derivative: dodecanoic
and tetradecanoic acids are site-speci cally linked to
the 3-hydroxy groups of N- and O-bound hydroxyte-
tradecanoic acid residues, respectively.34),35)
Chemical synthesis of the newly elucidated struc-
ture of the biosynthetic precursor 13, designated pre-
cursor Ia and later renamed lipid IVa, was suc-
cessfully achieved by combining similar procedures
elaborated in our preceding works toward the ‘‘old’’
structures.36),37) The  rst chemical synthesis of the
complete structure of mature E. coli type lipid A 14
immediately followed.34),38) Because of the unsym-
metrical pattern of acylation on the two glucosamine
Fig. 5. The chemical structures of a tetraacylated biosynthetic precursor of lipid A (13) and E. coli lipid A (14).
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plex than that for the symmetrically acylated 13.
The following basic strategy was thus elaborated:
1) All persistent protecting groups were selected to
enable mild hydrogenolytic removal at the  nal step.
This should facilitate puri cation of the  nal amphi-
philic product. 2) In order to reduce the number of
protecting groups required, all the acyl groups and
the protected 4’-phosphate were introduced at the
stage of monosaccharide precursors. 3) Only the N-
acyl group of the distal glucosamine residue was
exceptionally introduced after the formation of the
disaccharide. This was because N-3-acyloxyacyl groups
on 2-amino sugar moieties were found to undergo b-
elimination to form a,b-unsaturated acyl derivatives
when their glycosidic positions were activated for
glycosylation reactions. The 2,2,2-trichloroethoxy-
carbonyl (Troc) group was used for the protection of
this particular 2-amino group during glycosylation.
This group was known to assist desired b-glycosila-
tion by 2-amino-2-deoxy sugar moieties in good
yields and could be selectively removed after the for-
mation of the disaccharide in our previous work.30),31)
4) The glycosyl phosphate moiety was introduced at
the  nal synthetic stage just before the hydrogeno-
lytic deprotection. This was a strategy to retain
the chemically labile particular phosphate residue.
Figure 6 illustrates the  rst synthesis of 14 according
to this line.
The biological activities of the synthetic lipid A
according to the revised structures (13 and 14) were
immediately tested by our collaborating groups.39)–42)
The preparations showed de nite endotoxic activity
including both bene cial and detrimental ones de-
scribed for natural lipid A of bacterial origin. The
former 13, in particular, therefore represents the  rst
synthetic compound which did reproduce the endo-
toxic responses in both in vivo and in vitro test sys-
tems.39),40) The latter 14 showed indistinguishable
activity with a natural counterpart isolated from
E. coli cells.41),42) The  nal and complete evidence
was thus obtained in support of the concept that
lipid A is the active entity of bacterial endotoxin
almost hundred years after Pfei er had  rst described
endotoxin in 1892. Long-concerned possible in uence
of any contaminants of bacterial origin was thereby
completely excluded.
Successful chemical synthesis of lipid A not only
meant the simple con rmation of its chemical struc-
ture but simultaneously had opened a new horizon
in endotoxin research. Lipid A derivatives of any
structures had become synthetically accessible in
pure states. In the meantime many lipid A analogues
were isolated from various bacteria and their struc-
tures elucidated. Some of the analogous structures
were then synthesized, where synthetic procedures
were improved in various aspects to attain higher
ef ciency and yields. As one of the representative ex-
Fig. 6. The  rst chemical synthesis of E. coli lipid A (14).
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shown in Fig. 7.43) By the use of many structural
analogues synthesized, the relationship between chem-
ical structures and biological activities were precisely
studied on this group of glycolipid.44)–49)
A typical example where a striking e ect of the
structure was observed is an antagonistic function of
the biosynthetic precursor 13. In our earlier work
where the toxicity of preparations was determined
by in vivo test on mice, both tetraacylated 13 and
hexaacylated 14 exhibited potent positive activity.
When they were tested by an in vitro human cell-
line system, the former showed no capacity to in-
duce in ammatory cytokines such as TNF-a and
interleukin-6 (IL-6) but even inhibits their induction
by LPS.50),51) This was discovery of an antagonistic
compound which inhibits the action of LPS or its
active principle lipid A on human cells. New possibil-
ities became realistic to  nd antagonistic compounds
to be used clinically to suppress the toxic e ects of
LPS. Additional examples of antagonistic lipid A
were then discovered from other bacterial species by
other research groups,52),53) which led to chemical
synthesis of arti cial antagonistic molecules to be of
possible value in clinical application against bacterial
sepsis.54),55)
Chemical synthesis allows creation of arti cial
molecules never available from natural sources. Vari-
ous natural and unnatural derivatives of lipid A were
synthesized with di erent number, location, and chain
length of acyl groups and their in uence on the bio-
logical activities has been accumulated.43),55)–60) Ad-
ditional structural modi cation of lipid A can also
be possible: either one or even both of the phosphate
groups can synthetically be substituted by other
acidic groups without loosing the original biological
activity.43),61) 1-O-Phosphonooxyethyl (PE) analogues
(15 and 16) among such products, in particular,
were quite valuable since substitution of the glycosyl
phosphate groups improved the stability of the prod-
ucts and hence their synthesis and puri cation were
much easier than the natural type compounds.43)
This merit was utilized in the synthesis of pure
tritium-labeled bioactive lipid A derivatives (15a
and 16a) with high speci c radioactivity.62) The PE
analogues (15 and 16) show indistinguishable activ-
ity with those of natural type biosynthetic precursor
and mature E. coli lipid A (13 and 14), respectively:
the former was antagonistic while the latter endo-
toxic.61) These labeled compounds were subjected
to experiments aiming at direct identi cation of lipid
A-binding proteins on animal cell but the attempt
failed to obtain clear-cut informationn.62) The labeled
compounds were utilized in analyzing the interaction
of lipid A and its binding receptor complex dis-
covered after  ve years as described later.
Fig. 7. Improved synthetic route to E. coli lipid A (14).
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lipopolysaccharide
After substantial knowledge has been accumu-
lated on the structure-activity relationship of the
lipid A residue, our next attempt was directed toward
synthesis of more complex structure present in natural
LPS. Though lipid A was undoubtedly concluded
to be a structural moiety responsible for exertion of
endotoxic activity, this glycolipid is always accom-
panied with a covalently bound saccharide chain
when present on bacterial cell surface. Since the roles
of the additional saccharide parts were not precisely
studied yet, we decided to start total chemical syn-
thesis of an LPS molecule actually present on living
bacterial cell wall. The target selected was the LPS
produced by E. coli Re mutant. This mutant has
deep de ciency in the biosynthetic system and pro-
duces LPS lacking most of the saccharide chain but
a disaccharide linked to the 6’-positions of lipid A.
This molecule 17, whose structure was previously
determined by us,63) provides with a good model for
elucidation of the role of additional sugar units
linked to lipid A on the biological activity.
Even though 17 is the smallest member of the
LPS family, its complex architecture and the presence
of the unique eight carbon acidic sugar, 3-deoxy-D-
manno-octulosonic acid (formerly called 2-keto-3-
deoxyocutonic acid and thus traditionally abbreviated
Kdo) makes the synthesis a real challenge for chem-
ists. The ketosidic linkage of Kdo is quite labile to
acidic treatments, which was the reason enabled
Westphal and L€ uderitz to discover liberation of lipid
A by mild acid hydrolysis of LPS. The presence of
both base-labile acyl groups and the acid-labile
glycosyl phosphate and Kdo in the target molecule
required elaboration of mild reaction conditions for
most transformation steps. An ef cient method for
regio- and a-selective formation of ketosidic linkages
of Kdo had also to be established. Selective protec-
tion and deprotection during synthetic steps were
additional important issues.
The synthetic route to 17 was so designed that
we can utilize the knowledge accumulated through
our synthetic works on lipid A.47)–49) Thus, the two
Kdo units were introduced stepwise to a glucosamine
disaccharide portion corresponding to lipid A that
already had all acyl groups at the required positions.
The basic strategy was also maintained where the
glycosyl phosphate was introduced at the last stage
just before the  nal hydrogenolytic deprotection, as
in the case of lipid A synthesis. Since the presence of
a protected 4’-phosphate proved to inhibit coupling
of the Kdo residue at the 6’-hydroxy group of the dis-
Fig. 8. Chemical structures of phosphonooxyethyl analogues (15 and 16) of lipid A.
Fig. 9. Chemical structure of E. coli Re LPS (17).
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troduced after the coupling of the  rst Kdo with the
glucosamine disaccharide.64)
Coupling of 4,6-O-benzylidene-N-Troc-glucosa-
mine trichloroacetimidate (18) with another glucosa-
mine unit (19) having free 3- and 6-hydroxy groups
resulted in the selective formation of the desired
b(1-6) glucosamine disaccharide (20), to which the
acyl groups at the 3-O- and 2’-N-positions were then
introduced stepwise. After the removal of the benzy-
lidene-protecting group, the primary 6’-hydroxy
group was converted into triethylsilyl ether for selec-
tive activation for the subsequent reaction with a
Kdo donor.64)
Fig. 10. Synthetic route to E. coli Re LPS (17).
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units was e ected using suitably protected Kdo
 uorides as donors. A new route was elaborated in
our previous work for the construction of the eight-
carbon skeleton of Kdo starting from a D-mannose
derivative and a dithioacetal of glyoxylic acid.65),66)
Two Kdo  uorides 21 and 22 were prepared via
this route with some modi cations according to
van Boom et al.67) Lewis acid-catalyzed reactions of
Kdo  uorides with hydroxy groups activated as silyl
ethers proceeded smoothly in good yields.68) Kdo
donors having sterically demanding protecting groups
such as isopropylidene or TBS groups on the 4- and
5-positions, gave satisfactorily high a-selectivity be-
cause the access of the glycosyl acceptor from the b-
face of the Kdo donor is hindered.64),68)
Coupling of the  uoride 21 and the lipid A part
disaccharide 23 devoid of the 4’-phosphate pro-
ceeded smoothly to give the desired trisaccharide 24
containing a-linked Kdo in excellent stereoselectivity
and high yield. The free 4’-hydroxy group of 24 was
then phosphorylated by the phosphoramidite method
to a ord a bisphosphorylated trisaccharide 25,w h o s e
both TBS groups were then removed and the 4’’-
hydroxy group of the product selectively converted
to its triethylsilyl ether. To this position the second
Kdo was introduced by using the 4,5-O-isopropyli-
dene protected Kdo  uoride 22. The reaction suc-
cessfully proceeded again with perfect a-selectivity
to complete the tetrasaccharide backbone of Re
LPS. The TBS-protected donor 21 gave lower yield
when used at this step probably because of the too
large steric demand of the TBS groups. The iso-
propylidene groups of the resultant tetrasaccharide
derivative 26 were removed under mild acidic con-
ditions, where acid labile ketosidic linkages were re-
tained. After cleavage of the allyl glycoside, the free
glycosidic position was selectively phosphorylated to
give the desired protected Re LPS 27, which was
subjected to the  nal hydrogenolytic deprotection to
give the  rst synthetic Re LPS 17.64)
From the result of biological tests of the syn-
thetic compound, the e ect of the Kdo residues was
clearly shown to enhance the potency of lipid A in
activation of the innate immune system. For exam-
ple, synthetic Re LPS 17 showed higher IL-6 induc-
ing activity than synthetic E. coli lipid A.64) By ap-
propriate modi cations of the above synthetic route
to 17, a compound with one Kdo linked to lipid A
was also prepared. More recently, chemical synthesis
was achieved of further Kdo-containing lipid A
derivatives corresponding to partial structures of
Helicobacter pylori LPS.69) Comparison of the bio-
logical activity of such synthetic compounds gave
further proof of the e ect of the Kdo residues.
Concluding remarks
Through the long-termed intensive research on
the activation of the immunological system of higher
animals by bacterial cell components, the overall pic-
ture of innate immunity has been gradually unveiled.
Innate immunity is the  rst line basic defense system
of animals against invading microorganisms. When
we started our synthetic works on PGN and LPS
aiming at the characterization of essential structural
elements of these bacterial high molecular com-
ponents, we thought it quite rational that typical
and vital components of microbes are recognized as
the sign of invasion and trigger the defense system
of hosts, though the general idea of innate immunity
was not established yet. When the  rst synthetic
specimen of MDP and lipid A became available, their
biological activities were tested by in vivo systems for
evaluation of leukocyte migration and antibody level
in guinea pigs, pyrogenicity in rabbits, lethal toxicity
in mice and so on. Later, activities were more quan-
titatively determined by measuring the amounts of
individual cytokines secreted from cells by using the
ELISA technique. Various cell lines including cul-
tured human cells also became available, which led
to the discovery of the antagonistic activity of 13
and 15 as described above.
Several proteins such as LPS-binding protein
(LBP) and CD14 that bind to LPS and lipid A have
been identi ed in sera or cell surfaces of higher ani-
mals.70),71) However, they are either soluble or cell
surface proteins that lack the intracellular domains
essential for the transfer of signals into cells. After
the discovery of a membrane protein named Toll,72)
which participates in the defense of insects against
fungi, in 1996, revolutionary advances were brought
about in our understanding of innate immune recep-
tors. Members of the mammalian Toll-like receptor
(TLR) family were soon characterized by homology
search. TLRs are membrane proteins sharing the
same structural features of extracellular leucine-rich
repeats and intracellular IL-1 receptor-like signaling
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ous microbial cell components by individual TLRs
and signaling system thereafter are now well under-
stood.4),74) TLR4 among them was proved to be the
speci c receptor for lipid A, a decisive evidence being
obtained by the use of our synthetic pure lipid A
specimen.75) Miyake et al. then found that an addi-
tional protein named MD2 which is bound to TLR4
is essential for the recognition of lipid A by the
latter.76) They further analyzed the mechanism of
lipid A recognition by TLR4-MD2 complex by the
use of our synthetic radio-labeled derivatives of lipid
A 16a and antagonistic precursor 15a.77)–79) More
recently, direct crystallographic structure was ob-
tained for a complex of our synthetic lipid A pre-
cursor with MD280) and then for a complex of other
arti cial lipid A antagonist with TLR4-MD2 by
other independent group.81) Dimeric structure of
TLR-MD2-LPS ternary complex was then deter-
mined by X-ray crystallographic analysis as well to
explain the receptor activation mechanism.82) The
precise molecular mechanism of lipid A recognition
as a key bacterial component is being unveiled from
various directions.
It is a rational and sophisticated strategy of
higher animals to use ubiquitous cell components
essential for the survival of bacteria. Bacteria can
not escape this defense system because they are nei-
ther alive without these structural units of their cells
nor allowed to basically modify the structure of their
essential elements. Our synthetic works described in
this article have promoted general understanding of
this highly important innate immune system by giv-
ing concrete molecular basis of pure key substrate
molecules and thus clear-cut results in biological in-
vestigations. Various physicochemical investigations
have also become possible by the use of pure mole-
cules,83) though not described in this article, new
routes having been opened to investigate interaction
and molecular behavior of the key molecules, lipid A
and LPS, on lipid membranes.84),85) Such approaches
are expected to give information on the very early
stage of innate immune processes. Quite other direc-
tion of researches has also now emerging on the
TLR systems of animals other than mammals by
several research groups including ourselves.86) Such
approaches may also give new information from evo-
lutional aspects and help understand the origin and
signi cance of our own defense system of innate
immunity.
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